Benefits

LGG^® is one of the world’s most researched probiotic strains with 1000+ scientific publications and over 300 in humans.¹ Isolated by Gorbach and Goldin in 1985, LGG^® has unique hair-like appendages called pili which increase its persistence in the gastrointestinal tract where it is able to exert positive health benefits.² A direct comparison of commercialised GG probiotics (against LGG^®) showed major DNA segments to be missing with pili encoding genes among these.³ Manufacturing and growth mediums can also effect both the genetic expression and survival of pili.⁴ Metagenics have exclusively used trademarked LGG^® since 2008, guaranteeing strain and manufacturing authenticity, and matching the majority of human clinical trials.

Allergy: Higher doses of LGG^® (20 billion CFU ) have been shown to up regulate anti-inflammatory interleukins (IL-10)⁶ and down regulate ImmunoglobulinE (IgE) synthesis.⁷ In addition to a significant amount of research in infants and prenatally, a 2015 clinical trial showed a reduction in peanut allergy in children when used in conjunction with a desensitisation program.⁸ Metagenics supports Professor Mimi Tang’s research in childhood food allergy at the Murdoch Children’s Research Institute and are product suppliers for a follow-up study in peanut allergy.

Gastrointestinal Use: Diarrhoea: LGG^® (10-20 billion CFU) reduces the frequency, severity and duration of diarrhoea – viral, travellers and also antibiotic associated.¹⁰

Microbiome Use: Regeneration of core commensal (native) gut flora: More recently DNA sequencing of the microbiome has shown LGG^® has the ability to influence and regenerate commensal bacterial families.¹¹

Prenatal Use: LGG^® has a wide body of evidence showing reduced allergy, eczema and atopy when taken prenatally.^{12, 13, 14} More recent research has shown support for maternal glucose control, maternal and childhood obesity¹⁵ and reduced incidence of childhood behavioural complaints (when taken during pregnancy and infancy).¹⁶